Table 1.
Participant characteristics by randomization arm at baselinea
| UC (N=95) | CES (N=95) | |
|---|---|---|
| Demographics | ||
| Annual Household Income >$100,000 | 40.00% | 36.84% |
| Mean Age, years (SD) | 51.8(14.0) | 53.4(12.5) |
| College & Graduate Degree | 55.79% | 57.90% |
| Female | 56.84% | 46.32% |
| Employed | 58.95% | 71.58% |
| Now Married | 63.16% | 69.47% |
| Household Size >=2 | 78.95% | 86.32% |
| Race (self-reported) | ||
| Hawaiian / Other Pacific | 1.53% | 0.00% |
| Islander | ||
| Black/African American | 0.00% | 1.53% |
| Asian | 2.11% | 8.42% |
| American Indian/Alaska | 10.53% | 8.42% |
| Native | ||
| White | 84.2% | 81.1% |
| CRCP History | ||
| CRC Diagnosis | 36.84% | 33.68% |
| Colon Polyps | 86.32% | 80.00% |
| UC Testing Receivedb | ||
| None | 2.11% | 2.11% |
| MSI and/or IHC | 3.16% | 5.26% |
| BROCA™ panelc. | 18.95% | 21.05% |
| Commercial paneld. | 22.11% | 21.05% |
| ColoSeq™ e. | 53.68% | 53.68% |
No statistically significant differences for any characteristics between the two arms
Numbers might not add up to 100% because some participants received more than one type of UC
The BROCA™ pan cancer gene panel included the following genes at the start of the study: APC, ATM, ATR, BABAM1, BAP1, BARD1, BMPR1A, BRCC36, BRIP1, CDH1, CDK4, CDKN2A, CHEK1, CHEK2, EPCAM, FAM175A, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PRSS1, PTEN, RAD50, RAD51B, RAD51C, RAD51D, RBBP8, RET, SMAD4, STK11, TP53, TP53BP1, UIMC1, VHL, XRCC2, and XRCC3. The following genes were added to the BROCA™ panel during the course of the study: AKT1, AXIN2, BRCA1, BRCA2, CTNNA1, FANCM, FH, FLCN, GALNT12, GEN1, GREM1, HOXB13, MEN1, MET, MITF, NF1, NTHL1, PALLD, PDGFRA, PIK3CA, POLD1, POLE POT1, PRKAR1A, PTCH1, RB1, RECQL, RINT1, RPS20, SDHB, SDHC, SDHD, SLX4 and SMARCA4. The following genes were removed from the BROCA™ panel during the course of the study: BABAM1, BRCC36, RAD50, RBBP8, STK11, TP53BP1, UIMC1 and XRCC3.
Other panels included colon cancer and pan-cancer panels from GeneDx (N = 35), Myriad Genetics (N = 2), Ambry Genetics (N = 1) and Invitae (N = 1)
See Figure A.1 for genes included on the ColoSeq™ panel throughout the course of the study.